Table 1 Demographics.

Continuous data are mean (SD). The lower part shows percentage with positive tau markers, using a priori cut points, with 95% CIs from a bootstrap procedure. Frequency of positivity was compared by Fisher’s exact tests. Statistical comparisons for biomarkers across groups are shown in Fig. 1. CDR, Clinical Dementia Rating scale; M, male; F, female.

CU+ CU+
mild cognitive deficits
+
AD dementia
N18403835
Age, years73.9 (4.7)75.0 (7.4)71.8 (7.2)72.0 (7.0)
Sex, M:F11:716:2424:1420:15
APOE ε4, −/+ (%+)15/3 (17%)19/21 (53%)7/31 (82%)12/20 (63%)
Education, years12.8 (3.8)11.9 (4.0)12.2 (3.5)12.2 (3.7)
MMSE, points of29.1 (1.1)29.1 (1.1)25.6 (3.1)20.5 (5.3)
CDR000.51–3
CSF P-tau217, ng/liter70.9 (32.6)223.3 (135.3)634.1 (404.3)883.7 (530.8)
CSF P-tau181, ng/liter82.6 (26.7)177.3 (80.3)341.9 (152.1)429.5 (208.6)
CSF T-tau, ng/liter267.5 (62.1)403.6 (114.7)550.4 (156.7)587.7 (208.5)
Tau PET ITC, SUVR1.19 (0.07)1.20 (0.07)1.79 (0.60)2.21 (0.49)
Tau PET Braak V–VI, SUVR1.03 (0.05)1.02 (0.05)1.27 (0.31)1.48 (0.34)
Tau biomarker positivity, % (95% CI)
CSF P-tau217 (>119.5 ng/liter)5.6 (0–18.8)*†‡70.0 (56.1–84.1)†‡100 (100–100)97.1 (90–100)
CSF P-tau181 (>152.6 ng/liter)5.6 (0–18.8)*†‡55.0 (39.5–70.3)†‡89.5 (78.4–97.7)97.1 (90–100)
CSF T-tau (>464.7 ng/liter)0 (0–0)*†‡22.5 (10.5–35.3)†‡71.1 (55.6–85.1)74.3 (60–88.9)
Tau PET ITC (>1.31 SUVR)0 (0–0)†‡2.5 (0–8.3)†‡76.3 (60.9–89.7)100 (100–100)
Tau PET Braak V–VI (>1.28 SUVR)0 (0–0)†‡0 (0–0)†‡31.6 (17.2–45.9)65.7 (48.8–80)

*P < 0.05 versus Aβ+ CU.

P < 0.05 versus Aβ+ with mild cognitive deficits.

P < 0.05 versus Aβ+ AD dementia.